HYBIO Pharmaceutical and MCG Pharma signed product licensing agreement to jointly expand the Turkish market
On April 10, 2026, Shenzhen Hybio Pharmaceutical Co., Ltd. ("Hybio Pharma") and MCG Pharma İlaç Sanayi ve Ticaret Limited Şirketi ("MCG Pharma"), a well-known Turkish pharmaceutical and healthcare company, successfully held a licensing agreement signing ceremony for Liraglutide injection and Semaglutide injection. This marks the successful entry of Hybio Pharma's core products, Liraglutide and Semaglutide, into the Turkish market, becoming a key step in the company's internationalization strategy in the Middle East.
At the signing ceremony, Tang Yangming, Director and Executive President of Hybio Pharma, and Kürşat Genç, CEO of MCG Pharma, inked the agreement on behalf of their respective companies. The signing was witnessed by senior executives from both sides, including Zeng Shaogui, Chairman and President of Hybio Pharma; Chen Ye, Senior Sales Director; Meltem Genç, Deputy General Manager of MCG Pharma; and Batuhan GÜNER, Business Development Director.
According to the agreement, Hybio Pharma granted MCG Pharma the exclusive commercialization rights for its Liraglutide and Semaglutide related products in Turkey. The two parties will engage in comprehensive, in-depth collaboration across product registration, market access, localization and follow-up services.
Mr. Zeng Shaogui, President of Hybio Pharma, stated, "Turkey is a core hub in the Middle Eastern pharmaceutical market, and MCG Pharma has been deeply involved in the local pharmaceutical and healthcare field for over forty years, possessing a well-established channel network and mature market operation experience. This collaboration is a significant measure that leverages the strengths of both parties, and will help the company's core products quickly enter the Turkish market, further improving its global business layout. "
Mr. Kürşat Genç, CEO of MCG Pharma, pointed out that Liraglutide and Semaglutide are core drugs for treating diabetes and obesity, with Semaglutide experiencing continuously rising demand in the Turkish market. Hybio Pharma has strong capabilities in the R&D and manufacturing of peptide drugs, and its products have received authoritative certifications from multiple countries. He believes that the collaboration between the two parties will effectively seize market opportunities, improve the accessibility of high-quality drugs in the local market, and provide Turkish patients with more treatment options.
About Hybio Pharmaceutical:
Hybio Pharmaceutical Co., Ltd., a national high-tech enterprise, specialized in R&D, production and marketing of peptide drugs for more than 20 years, with a complete formulation pipeline covering the global mainstream peptide targets, including but not limited to the original innovative drug of GLP-1R/GIPR/GCGR triple receptor agonist, as well as blockbuster peptide ANDA formulations such as Retatrutide, Tirzepatide, Semaglutide, and Liraglutide. The company holds nearly 500 authorized patents domestically and internationally. It was the first company in the world to obtain FDA approval for the ANDA of Liraglutide, a GLP-1 daily injection. Its products have entered the regulated markets including Europe and the United States.
About MCG Pharma:
MCG Pharma, with over forty years of experience in the pharmaceutical and healthcare industry, is a member of the Genç Pharmacy Group. The company has established an R&D laboratory focused on high-value projects beneficial to the national economy. Through international product licensing and collaboration with global partners, MCG provides innovative treatment solutions for "rare diseases." The company is committed to long-term investment in the health sector, aiming to become a leader in the industry. To achieve this goal, MCG is progressing with the registration of its wholly-owned oncology drug and is actively engaged in licensing and introducing biological drugs.